Form D · Pharmaceuticals
InMed Pharmaceuticals Inc.
Vancouver, A1 · CIK 0001728328
Offering snapshot reported Dec 6, 2022 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 21, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 6, 2022 | Initial | $6,000,177 | No comparison | 2 | SEC filing |
| Jun 8, 2022 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Oct 28, 2021 | Initial | $4,305,000 | No comparison | 54 | SEC filing |
| Jul 19, 2021 | Initial | $12,000,000 | No comparison | Not reported | SEC filing |
| Jan 17, 2018 | Initial | $1,633,700 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $450K
- Finders' fees
- $0
- Form D file number
- 021-466617
Consists of (i) $6,000,010.50 received and (ii) approximately $166.82 to be received upon exercise of pre-funded warrants sold in the offering to purchase up to an aggregate of 1,668,185 common shares at an exercise price of $0.0001 per share.
In addition to the $450,000, the issuer paid to the sole placement agent in the offering, a management fee of $60,000, $20,000 for non-accountable expenses and $35,000 for fees and expenses of legal counsel and other out-of-pocket expenses.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Dec 6, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric A. Adams | Director, Executive |
| Bryan Baldasare | Director |
| Martin Bott | Director |
| Jeff Charpentier | Executive |
| Bruce S. Colwill | Executive |
| Adam Cutler | Director |
| Brenda Edwards | Executive |
| William J. Garner | Director |
| Janet Grove | Director |
| Sazzad Hossain | Executive |
| Eric C. Hsu | Executive |
| Andrew Hull | Director |
| Nicole Lemerond | Director |
| Sarah Li | Executive |
| Alexandra D.J. Mancini | Executive |
| Catherine A. Sazdanoff | Director |
| Michael Woudenberg | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
815 W. Hastings Street Suite 310
Vancouver, A1, V6C 1B4
Vancouver, A1, V6C 1B4